Friedreich’s Ataxia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of Friedreich’s ataxia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of Friedreich’s ataxia for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 20 years for all countries covered in this report.
Clarivate Epidemiology’s Friedreich’s ataxia forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Friedreich’s ataxia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts five Friedreich’s ataxia patient populations, as follows:
- Diagnosed prevalent cases.
- Diagnosed prevalent cases with diabetes.
- Diagnosed prevalent cases without diabetes.
- Diagnosed prevalent cases with cardiomyopathy.
- Diagnosed prevalent cases without cardiomyopathy.
Note: Coverage may vary by country.
